Turkmenistan Law No. 319-V on Drug Provision: The Backbone Law for Devices

1. Key takeaways

Law No. 319-V of Turkmenistan on Drug Provision (January 12, 2016) is the backbone law for medical device registration and circulation in Turkmenistan. It provides:

• The purpose of national registration: to determine whether medicines and medical devices meet the requirements of this law and other laws and regulations of Turkmenistan, and to prevent medicines and medical devices that may endanger human life and health, as well as human genetics, from being imported into Turkmenistan, produced and circulated;
• The body implementing national registration: the authorized body (under the Ministry of Health), acting in accordance with the Regulation on the State Registration of Medicines and Medical Devices approved by the Ministry of Health;
• Four categories of products exempted from national registration;
• A framework for procedure timelines, validity of the registration certificate, variations and renewal.

One law governing both medicines and devices is a structural fact of this market.

2. Legal basis

3. Expert insights

Insight 1: three prohibited activities are hidden inside the wording on the purpose of national registration.

In the statutory wording on the purpose of national registration, the activities to be prevented are import into Turkmenistan, production, and circulation. The three activities are listed in parallel, which means that an unregistered device cannot only not be sold — it also cannot be imported, cannot be produced, and cannot circulate within the territory. This is the other side of the mandatory registration red line developed in Article 04 of this series.

Insight 2: the reference to human genetics is a typical feature of post-Soviet legislative language.

Law No. 319-V lists human genetics alongside life and health as protected objects. This wording derives from the biosecurity legislative tradition of the post-Soviet space, and in practice it means that products involving genetic material, reproduction and genetic testing are treated with particular caution. Genetic testing reagents within IVD should expect a higher intensity of review.

Insight 3: inconsistent English titles do not affect the reliability of the number and the date.

During this verification round, the law appeared in English-language sources under several titles, including On Drug Provision, On Medical Supplies, On Medicines Supply and On Medicines Provision. The titles differ, but the number (319-V) and the date (January 12, 2016) are fully consistent, showing that these are not different laws but different English renderings of the same law. We refer to it uniformly as the Law on Drug Provision, always with the number and the date.

Insight 4: the statute is the framework, the regulation is the operating manual — and the regulation is not published.

Law No. 319-V delegates procedural content to the regulation approved by the Ministry of Health. The practical consequence is that the certainty the statute itself gives you (180 days, 5 years, 30 days) is limited; the document list that actually decides success or failure sits in the regulation, and the current version must be obtained through the local representative.

Insight 5: the relationship with the 2015 foundational law determines the health-rights character of the regime.

Law No. 319-V was adopted about 8 months after the Law on the Protection of Citizens’ Health (May 23, 2015). Together they form a complete chain from health protection to the supply of medicines and devices. When interpreting provisions, the protection of citizens’ health should be treated as the legislative benchmark — which also explains why Turkmenistan brings medical cosmetics, disinfection products and medicinal mineral water into national registration (see Article 08).

4. Practical recommendations

1. In all external and internal documents, refer to the law as Law No. 319-V on Drug Provision (January 12, 2016); the number and date must never be omitted.
2. Build the registration plan on the shared drug-and-device regime, and do not set process milestones based on experience with independent device regulation.
3. For projects involving genetic testing and reproductive-health IVD, allow greater dossier depth and longer communication time.
4. Obtain the current Regulation on the State Registration of Medicines and Medical Devices through the local representative and use it as the final basis for the document list.
5. Set up a mechanism to track amendments of the law: once an amendment is officially announced, re-check whether the three figures — 180 days, 5 years, 30 days — have changed.

5. Verification checklist

• □ The regulatory library entry records No. 319-V together with January 12, 2016.
• □ It is confirmed that the purpose of national registration covers import, production and circulation.
• □ Genetic and reproductive IVD projects have resources reserved for a higher review intensity.
• □ The current Regulation on the State Registration of Medicines and Medical Devices has been obtained.
• □ A mechanism for tracking amendments of Law No. 319-V is in place.

Regulatory information verified as of October 30, 2026. The content cited in this document was checked against Law No. 319-V on Drug Provision (January 12, 2016; the number and date confirmed across no fewer than four independent sources) and the Regulation on the State Registration of Medicines and Medical Devices approved by the Ministry of Health; the ministry website was verified by direct access.

GRZAN support in Turkmenistan: GRZAN provides registration support to manufacturers, importers and authorized representatives for this market. Local resources can be coordinated, including licensed importing entities and authorized representative arrangements, covering national registration submission, the consular legalization chain for documents, delivery of samples, alignment with mandatory TDS certification, and customs clearance support. Service capabilities include classification judgment, selection of the registration pathway, preparation of dossiers in the national format, notarization and consular legalization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, and vigilance and post-market maintenance. Contact: info@grzanglobal.com.